Copyright
©The Author(s) 2017.
World J Nephrol. May 6, 2017; 6(3): 132-142
Published online May 6, 2017. doi: 10.5527/wjn.v6.i3.132
Published online May 6, 2017. doi: 10.5527/wjn.v6.i3.132
Table 3 Exposure to allopurinol
| Baseline | During follow-up | |
| Patients (n) | 2752 | 2570 |
| Allopurinol | ||
| Mean dose used during the period (± SD) | 210.9 (± 97.5) | 243.3 (± 128.2) |
| Proportion of patients taking < 300 mg (%) | 64.7 (1782) | 53.5 (1374) |
| Proportion of patients taking 300 mg (%) | 33.5 (921) | 40.8 (1049) |
| Proportion of patients taking > 300 mg (%) | 1.8 (49) | 5.7 (147) |
| Febuxostat | ||
| Proportion of patients who received at least 1 claim of febuxostat (%) | 0 (0) | 0 (0) |
| Mean dose used during the period (± SD) | NA | NA |
- Citation: Perreault S, Nuevo J, Baumgartner S, Morlock R. Any link of gout disease control among hypertensive patients and onset of end-stage renal disease? Results from a population-based study. World J Nephrol 2017; 6(3): 132-142
- URL: https://www.wjgnet.com/2220-6124/full/v6/i3/132.htm
- DOI: https://dx.doi.org/10.5527/wjn.v6.i3.132